76 results about "Chimeric antibody" patented technology

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The present disclosure relates to an anti-Claudin 18.2 antibody and an application thereof. Specifically, the present invention relates to an anti-Claudin 18.2 antibody; a mouse-derived antibody, chimeric antibody, humanized antibody and antigen-binding fragment thereof which contain a CDR of the anti-Claudin 18.2 antibody, and a use thereof as a medicine. In particular, the present disclosure relates to a use of the anti-Claudin 18.2 antibody in the preparation of a drug for treating Claudin 18.2 positive diseases or disorders.

Provided in the present invention are an anti-CD155 antibody and the use thereof. Moreover, an obtained anti-CD155 chimeric antibody, a humanized anti-CD155 antibody, and a humanized affinity-matured anti-CD155 antibody can only specifically target and bind to a CD155 receptor and block the binding of CD155 to receptors TIGIT, CD96, and CD226 thereof, but also have the characteristic of not inducing the apoptosis of CD155 cells.

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

Genetically modified mice whose immunoglobulin loci are engineered to be inserted into gene segments of human immunoglobulin variable regions are disclosed, the mice being capable of normal reproduction and producing human-mouse chimeric antibodies comprising a human variable region and a mouse constant region. The invention also provides a method for preparing the genetically modified mouse and application of the mouse.

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The invention relates to the technical field of monoclonal antibodies, and discloses a monoclonal antibody for recognizing NMI protein and application of the monoclonal antibody. The monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO.4, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO.9. The monoclonal antibody for recognizing the NMI protein and the chimeric antibody of the monoclonal antibody have an excellent specific recognition effect on the hNMI protein and the mNMI protein, and can be used for researching biological functions.

The present invention provides anti-CD155 antibodies and their applications, and provides anti-CD155 chimeric antibodies, humanized antibodies, and affinity-matured humanized antibodies, which specifically target and bind to the CD155 receptor, inhibit the binding of CD155 to its receptors TIGIT, CD96, and CD226, and have the characteristic of not inducing apoptosis of CD155 cells.

The present invention provides anti-B7H3 antibodies and their application thereof A group of murine anti-B7H3 monoclonal antibodies are prepared by hybridoma technology, using recombinant B7H3 protein as immunogen. Human-murine chimeric antibodies generated from the aforementioned murine anti-B7H3 hybridomas are capable of specifically binding to recombinant B7H3 protein and membrane-bound B7H3 on tumor cell lines. The derived B7H3 scFv-CD3ε-engineered T cells exhibit a significant cytotoxic effect on B7H3-positive tumor cell lines. Therefore, the anti-B7H3 antibodies and B7H3 scFv-CD3ε-engineered T cells have great application prospects in treating or ameliorating B7H3-associated diseases.

The invention relates to the technical field of biomedicine, in particular to a monoclonal antibody specifically combined with EsxB and a therapeutic reagent. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions VLCDR1, VLCDR2 and VLCDR3, the heavy chain variable region comprises three complementary determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.1, and the heavy chain variable region is an amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.2; the therapeutic reagent comprises a monoclonal antibody, a single-chain antibody, a human-mouse chimeric antibody or a humanized antibody; the monoclonal antibody with high specificity, high neutralization activity and high protection force for EsxB provided by the invention has the characteristic of mediating complement-dependent cytotoxic effect, has excellent in-vivo antibacterial activity, and can support the construction of an anti-EsxB chimeric or humanized genetic engineering antibody with neutralization activity.

Provided are an anti-BCMA antibody, an antigen-binding fragment thereof, and a medical use thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR region of the anti-BCMA antibody, a pharmaceutical composition containing the anti-BCMA antibody or the antigen-binding fragment thereof, and the use of same as an anti-cancer drug and for treating autoimmune diseases. Particularly, provided are a humanized anti-BCMA antibody, and the use of same in the preparation of a drug for treating BCMA-mediated diseases or conditions and the use of same in disease detection and diagnosis.

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a drug for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

The present invention describes a chimeric antibody having specificity for FOLR1, a vector encoding the chimeric antibody, a recombinant host cell comprising the vector, and the use of the chimeric antibody in the preparation of bispecific antibodies and antibody drug conjugates.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

The application relates to the field of biomedical technology, in particular to a monoclonal antibody specifically combined with EsxA and a therapeutic reagent; the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementarity determining regions VLCDR1, VLCDR2 and VLCDR3, the heavy chain variable region comprises three complementarity determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an amino acid sequence identical to SEQ.ID.NO.1 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%, and the heavy chain variable region is an amino acid sequence identical to SEQ.ID.NO.2 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%; the therapeutic reagent comprises the monoclonal antibody, a single-chain antibody, a human-mouse chimeric antibody or a humanized antibody; the monoclonal antibody provided by the application is high in specificity, neutralization activity and protective power and is directed to EsxA, has the characteristics of mediating complement-dependent cytotoxicity, is excellent in in-vivo antibacterial activity and can support the construction of an anti-EsxA chimeric or humanized genetically engineered antibody with neutralization activity.

The present application belongs to the technical field of cellular immunization engineering, and particularly relates to a polypeptide specifically recognizing PSCA and application thereof. The polypeptide provided by the present application specifically recognizes PSCA and has good affinity performance. The polypeptide specifically targeting PSCA provided by the present application can mark PSCA positive cells, combine with PSCA antigen and PSCA positive cells, and can be used as a detection reagent for PSCA molecules and an in-vivo tracing labeling reagent. The polypeptide specifically targeting PSCA provided by the present application can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, and can be used in an immune cell treatment drug targeting PSCA to kill malignant tumors expressing PSCA. The polypeptide specifically recognizing PSCA of the present application is derived from a natural full human antibody, and compared with a mouse-derived antibody, a chimeric antibody and a humanized antibody, the immunogenicity is greatly reduced, and the safety can be maximally ensured in clinical application.

This invention relates to the field of antibodies, and particularly to anti-EphA2 antibodies and their applications. This invention provides anti-EPH receptor A2 (EphA2) antibodies and their uses. This application also provides chimeric and humanized antibody forms of anti-EphA2 antibodies. These antibodies have high affinity for the human EphA2 protein and are promising antibody molecules for the prevention and / or treatment of EphA2-related diseases, such as EphA2-related tumors, osteoporosis, Alzheimer's disease, etc.

The present invention relates to monoclonal anti-human-(IDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Provided are an anti-claudin 18.2 (CLDN18.2) antibody and use thereof. Also provided are a chimeric antibody and a humanized antibody of the anti-CLDN18.2 antibody. These antibodies have high affinity for human CLDN18.2 proteins, and are promising antibody molecules for preventing and / or treating CLDN18.2 related diseases, such as CLDN18.2-related tumors.

A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.

Disclosed in the present disclosure is genetically modified mice in which immunoglobulin loci are modified to insert gene segments of a human immunoglobulin variable region. The mice can be bred normally and produce human-mouse chimeric antibodies including a human variable region and a mouse constant region. The present disclosure also provides a method for preparing the genetically modified mice and use of the mice.

The present disclosure relates to anti-Claudin 18.2 antibodies and uses thereof. In particular, the present disclosure relates to an anti-Claudin 18.2 antibody; murine antibodies, chimeric antibodies, humanized antibodies and antigen-binding fragments thereof comprising the CDRs of the anti-Claudin 18.2 antibody, and uses thereof as a medicament. In particular, the present disclosure relates to the use of an anti-Claudin 18.2 antibody in the manufacture of a medicament for treating a Claudin 18.2 positive disease or disorder.

Provided herein are, inter alia, antibodies (e.g. humanized antibodies, chimeric antibodies, monoclonal antibodies, antibody fragments (e.g. scFvs)), which bind Cluster of Differentiation 84 (CD84) with high efficiency and specificity. The antibodies provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for treating cancer and other CD84-related diseases.

To provide compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.SOLUTION: The invention relates to enhanced CTLA4 blocking activity for CTLA4 ligands B7.1 and B7.2, enhanced effector function, or reduced binding to soluble CTLA4 relative to membrane bound or immobilized CTLA4. An antibody may comprise a light chain variable amino acid sequence having an amino acid sequence comprising a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO: 1, and a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO: 2.SELECTED DRAWING: Figure 1

The present disclosure provides antigen binding regions and chimeric antibodies, as well as methods of making and using the same.

The invention relates to the technical field of biomedicine, in particular to a monoclonal antibody specifically combined with EsxA and a therapeutic reagent. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions VLCDR1, VLCDR2 and VLCDR3, the heavy chain variable region comprises three complementary determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.1, and the heavy chain variable region is an amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.2; the therapeutic reagent comprises a monoclonal antibody, a single-chain antibody, a human-mouse chimeric antibody or a humanized antibody; the monoclonal antibody with high specificity, high neutralization activity and high protection force for EsxA provided by the invention has the characteristic of mediating complement-dependent cytotoxic effect, has excellent in-vivo antibacterial activity, and can support the construction of an anti-EsxA chimeric or humanized genetic engineering antibody with neutralization activity.

The present disclosure relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to PD-1 and block the interaction between PD-1 and PD-L1 / PD-L2. The present disclosure also relates to antibodies that are chimeric antibodies, humanized antibodies, bispecific antibodies, derivatized antibodies, single-chain antibodies, portions of fusion proteins, or bispecific antibodies. Nucleic acid molecules encoding the antibodies, hybridomas, and methods for expressing the antibodies are also provided. Pharmaceutical compositions comprising the antibodies are also provided. The present disclosure also provides uses of these antibodies for enhancing T cell function and upregulating cell-mediated immune responses for the treatment and prevention of various diseases.

Disclosed are B5 hybridoma and a B5 monoclonal antibody to Burkholderia mallei, Burkholderia pseudomallei, or Burkholderia thailandensis and methods of use. Also disclosed are isolated binding fragments, isolated antibody fragments, isolated monoclonal antibodies, isolated chimeric antibodies, and isolated humanized antibodies having the binding fragments of the B5 monoclonal antibody. Also disclosed are assays for detecting B. mallei, B. pseudomallei, or B. thailandensis in a sample, for detecting infection by B. mallei, B. pseudomallei, or B. thailandensis, and therapeutic methods for treating infections by B. mallei, B. pseudomallei, or B. thailandensis.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.